Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 534 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Reunión anual de la American Society of Clinical Oncology de 2022:... June 4, 2022 Benefit of Adjuvant Chemotherapy in Patients with ctDNA-positive Resected Stage II... July 30, 2026 Breakthrough SARS-CoV-2 Infection Following COVID-19 Vaccination in Patients with Cancer January 12, 2022 Hyperfractionated Intensity-Modulated Radiotherapy Decreases the Rate of Severe Late Complications and... March 7, 2023 Load more HOT NEWS FDA Approves Pembrolizumab with Chemoradiotherapy for FIGO 2014 Stage III-IVA Cervical... This Program Provides Free Mammograms And Breast Cancer Treatment Services To... Risk of Distant Recurrence of ER-Positive Breast Cancer in Premenopausal Women... Adding Gemcitabine to Cisplatin Once per Week Concurrently with IMRT Significantly...
